All Oncology News

Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.

Small oncology practices employing fewer than 50 full-time employees might consider looking to the Small Business Health Options Program offered through the Affordable Care Act.

A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.

An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.

A delay in the launch of the Centers for Medicare & Medicaid Services (CMS) web site that tracks the financial relationship between physician and industry may prevent physicians from fully reviewing the data.

Buckling to calls for transparency and a Wall Street Journal court case requiring the agency to provide public access to physician billing records, the Centers for Medicare & Medicaid Services (CMS) released a database containing transactions worth $77 billion by 880,000 physicians and physician practices certified to collect from Medicare

Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia

An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.

Community oncologists and hematologists who participate in the Medicare Electronic Health Records Incentive Program may be subject to fee adjustments from the agency beginning January 1, 2015.

While the sustainable growth rate (SGR) debate has been put off for 2014, what should physicians be looking to as the transition to ICD-10 has been delayed for the second time in two years?

The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.

Providers cited issues related to insufficient standards, concerns about how privacy rules can vary among states, difficulties in matching patients to their records, and costs associated with exchange

The next-generation EGFR inhibitor CO-1686 has demonstrated promising activity in T790M-positive patients with non-small cell lung cancer.

The Senate is expected to consider and vote on a bill passed by the House on March 27 that includes language to patch the sustainable growth rate (SGR) formula for 12 months and delay ICD-10 implementation until at least October 1, 2015

Esteemed Oncology Awards Program to Name Giants in 16 Distinct Categories

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

Ceritinib (LDK378) demonstrated an ORR of 58% and a median PFS of 7 months as a treatment for patients with ALK-positive non-small cell lung cancer.

It looks like trouble continues for a bill that would delay payment cuts to physicians who treat Medicare patients for one year

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

Practice managers who need to understand the ins and outs of Medicare's resource-based relative value scale (RBRVS) can purchase an updated physician guide from the American Medical Association.

A physician's confidence level in his genomic knowledge plays a significant role in attitudes towards genomic tests, especially in tests that look for changes in DNA that are taken from patients' tumor samples

Small practices face all the difficulties of health IT implementation without the benefit of big budgets and numerous staff to diffuse the burdens, according to EHRIntelligence.com.

Leader in Supportive Oncology at Perlmutter Cancer Center at NYU Langone Medical Center to Take Leadership Position with the American College of Physicians.

Patients were no more likely to switch away from lower-tiered physicians than higher-tiered physicians within their health plan, especially if the physician was considered the patient's personal doctor

The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature

Efforts to evaluate cancer survivorship programs are a daunting task according to a technical brief issued by the Agency for Healthcare Research and Quality.

The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions

After months of wrangling, a call for a vote by House Majority Leader Eric Cantor on an amended version of the Sustainable Growth Rate (SGR) Repeal and Medicare Provider Payment Modernization Act of 2014 (H.R. 4015).

Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.